Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.91 Million USD | 10.57% |
| 2022 | -3.26 Million USD | -46.61% |
| 2021 | -2.22 Million USD | 23.54% |
| 2020 | -2.91 Million USD | 23.55% |
| 2019 | -3.8 Million USD | 8.42% |
| 2018 | -4.15 Million USD | 9.66% |
| 2017 | -4.6 Million USD | 14.91% |
| 2016 | -5.41 Million USD | -116.61% |
| 2015 | -2.49 Million USD | -14.0% |
| 2014 | -2.19 Million USD | 9.78% |
| 2013 | -2.42 Million USD | -39.39% |
| 2012 | -1.74 Million USD | -1723.99% |
| 2011 | -95.52 Thousand USD | -39.25% |
| 2010 | -68.6 Thousand USD | 78.56% |
| 2009 | -320 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -411.96 Thousand USD | -2.98% |
| 2024 Q1 | -400.04 Thousand USD | 49.11% |
| 2023 Q4 | -786.05 Thousand USD | -66.26% |
| 2023 Q1 | -529.29 Thousand USD | -9.57% |
| 2023 Q3 | -472.79 Thousand USD | 58.21% |
| 2023 Q2 | -1.13 Million USD | -113.74% |
| 2023 FY | -2.91 Million USD | 10.57% |
| 2022 Q3 | -496.77 Thousand USD | 72.38% |
| 2022 Q1 | -485.76 Thousand USD | -29.95% |
| 2022 FY | -3.26 Million USD | -46.61% |
| 2022 Q4 | -483.05 Thousand USD | 2.76% |
| 2022 Q2 | -1.79 Million USD | -270.29% |
| 2021 Q2 | -570.05 Thousand USD | 3.45% |
| 2021 FY | -2.22 Million USD | 23.54% |
| 2021 Q1 | -590.44 Thousand USD | 13.67% |
| 2021 Q4 | -373.79 Thousand USD | 46.0% |
| 2021 Q3 | -692.25 Thousand USD | -21.44% |
| 2020 Q1 | -679.61 Thousand USD | 6.9% |
| 2020 FY | -2.91 Million USD | 23.55% |
| 2020 Q2 | -601.82 Thousand USD | 11.45% |
| 2020 Q3 | -946.79 Thousand USD | -57.32% |
| 2020 Q4 | -683.96 Thousand USD | 27.76% |
| 2019 Q4 | -729.99 Thousand USD | 43.47% |
| 2019 FY | -3.8 Million USD | 8.42% |
| 2019 Q1 | -812.99 Thousand USD | 21.22% |
| 2019 Q2 | -974.81 Thousand USD | -19.9% |
| 2019 Q3 | -1.29 Million USD | -32.46% |
| 2018 Q3 | -1.03 Million USD | -26.76% |
| 2018 Q1 | -1.27 Million USD | -53.11% |
| 2018 FY | -4.15 Million USD | 9.66% |
| 2018 Q4 | -1.03 Million USD | 0.31% |
| 2018 Q2 | -816.65 Thousand USD | 35.97% |
| 2017 Q2 | -2.17 Million USD | -290.63% |
| 2017 Q1 | -557.51 Thousand USD | 11.9% |
| 2017 FY | -4.6 Million USD | 14.91% |
| 2017 Q4 | -832.95 Thousand USD | 19.57% |
| 2017 Q3 | -1.03 Million USD | 52.45% |
| 2016 Q3 | -1.31 Million USD | 36.53% |
| 2016 Q1 | -1.4 Million USD | -18.52% |
| 2016 Q4 | -632.81 Thousand USD | 51.72% |
| 2016 FY | -5.41 Million USD | -116.61% |
| 2016 Q2 | -2.06 Million USD | -47.29% |
| 2015 Q3 | -469.87 Thousand USD | 4.82% |
| 2015 FY | -2.49 Million USD | -14.0% |
| 2015 Q4 | -1.18 Million USD | -151.77% |
| 2015 Q2 | -493.68 Thousand USD | -14.38% |
| 2015 Q1 | -431.63 Thousand USD | -153.09% |
| 2014 Q2 | -826.35 Thousand USD | -45.71% |
| 2014 FY | -2.19 Million USD | 9.78% |
| 2014 Q1 | -567.12 Thousand USD | -14.81% |
| 2014 Q4 | -170.54 Thousand USD | 72.81% |
| 2014 Q3 | -627.18 Thousand USD | 24.1% |
| 2013 Q4 | -493.97 Thousand USD | -15.46% |
| 2013 FY | -2.42 Million USD | -39.39% |
| 2013 Q1 | -1.02 Million USD | -70.43% |
| 2013 Q2 | -481.59 Thousand USD | 53.03% |
| 2013 Q3 | -427.81 Thousand USD | 11.17% |
| 2012 Q4 | -601.61 Thousand USD | -53.12% |
| 2012 FY | -1.74 Million USD | -1723.99% |
| 2012 Q1 | -430.78 Thousand USD | -2053.92% |
| 2012 Q2 | -430.6 Thousand USD | 0.04% |
| 2012 Q3 | -392.89 Thousand USD | 8.76% |
| 2011 Q3 | -20 Thousand USD | 0.0% |
| 2011 FY | -95.52 Thousand USD | -39.25% |
| 2011 Q4 | -20 Thousand USD | 0.0% |
| 2010 FY | -68.6 Thousand USD | 78.56% |
| 2010 Q4 | -20 Thousand USD | 0.0% |
| 2010 Q3 | -20 Thousand USD | 0.0% |
| 2009 FY | -320 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -118.614% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 42.126% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 83.642% |
| Nascent Biotech, Inc. | -2.22 Million USD | -30.924% |
| Rebus Holdings, Inc. | -664 Thousand USD | -339.675% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.567% |
| Qrons Inc. | -643.67 Thousand USD | -353.557% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -649.402% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.74% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -602.669% |
| Skye Bioscience, Inc. | -13.67 Million USD | 78.646% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.933% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 159.401% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1015.458% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.15% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -2.418% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -90.062% |
| Mesoblast Limited | -84.14 Million USD | 96.531% |
| Marizyme, Inc. | -34.08 Million USD | 91.435% |
| Genus plc | 6.4 Million USD | 145.616% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 129.966% |
| Pharming Group N.V. | -4.87 Million USD | 40.17% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -46.966% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -213.454% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 65.037% |
| ContraFect Corporation | -56.88 Million USD | 94.868% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 35.903% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -108.236% |
| IMV Inc. | -38.67 Million USD | 92.451% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -6.129% |
| MultiCell Technologies, Inc. | -722.81 USD | -403801.994% |
| ONE Bio Corp. | 13.68 Million USD | 121.339% |
| Accustem Sciences Inc. | -3.74 Million USD | 22.074% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.051% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -504.362% |
| Q BioMed Inc. | -3.44 Million USD | 15.271% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 182.47% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -11.11% |
| Biomind Labs Inc. | -1 Million USD | -189.168% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.689% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -0.627% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 56.085% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -56.591% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9647.075% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 81.604% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -51.062% |
| GB Sciences, Inc. | -1.42 Million USD | -105.521% |
| Alpha Cognition Inc. | -9.7 Million USD | 69.92% |
| HST Global, Inc. | -140.9 Thousand USD | -1971.894% |
| CSL Limited | 3.7 Billion USD | 100.079% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -159.528% |
| Halberd Corporation | -75.05 Thousand USD | -3789.999% |
| Enzolytics Inc. | -2.14 Million USD | -35.864% |
| Agentix Corp. | -1.37 Million USD | -112.825% |
| Resverlogix Corp. | -12.74 Million USD | 77.101% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 7.854% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.313% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -179.64% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -84.85% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 14.26% |
| AVAX Technologies, Inc. | 6.69 Million USD | 143.62% |
| Zenith Capital Corp. | -8.94 Million USD | 67.355% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.298% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -16658.188% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -18.903% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1602.205% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -45.626% |
| Kadimastem Ltd | -3.04 Million USD | 3.974% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -196.675% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -132.44% |
| BioStem Technologies, Inc. | -7.77 Million USD | 62.47% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1508.642% |
| LadRx Corporation | -3.82 Million USD | 23.647% |
| Cell Source, Inc. | -4.32 Million USD | 32.504% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -324.986% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -324.986% |
| NovAccess Global Inc. | -2.46 Million USD | -18.351% |
| Affymax, Inc. | -15.04 Million USD | 80.597% |
| Itoco Inc. | -919.14 Thousand USD | -217.628% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 31.119% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -160.898% |
| Mobile Lads Corp. | -554.55 Thousand USD | -426.453% |
| CytoDyn Inc. | -18.05 Million USD | 83.833% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -11498.903% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1226.55% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -416.969% |
| SYBLEU INC | -149.18 Thousand USD | -1856.994% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -60.734% |
| International Stem Cell Corporation | -663 Thousand USD | -340.338% |
| Bioxytran, Inc. | -3.82 Million USD | 23.578% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5446.056% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -14253.215% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 91.95% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -80.435% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -296.753% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 6.157% |
| Neutra Corp. | -229.48 Thousand USD | -1172.166% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 83.355% |
| PureTech Health plc | -146.19 Million USD | 98.003% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 86.416% |
| IXICO plc | -1.43 Million USD | -103.162% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 69.24% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.603% |
| CSL Limited | 3.81 Billion USD | 100.077% |
| Cellectis S.A. | -108.85 Million USD | 97.318% |